Skip to content

Bupivacaine liposome injection for acute pain after thoracic surgery Efficacy and Safety of Pain Management : A Multicenter, Prospective, True Real world research

Bupivacaine liposome injection for acute pain after thoracic surgery Efficacy and Safety of Pain Management : A Multicenter, Prospective, True Real world research

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094672
Enrollment
Unknown
Registered
2024-12-25
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain after thoracic surgery

Interventions

Bupivacaine Liposome:None

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Understand the nature, significance, and possible benefits of the trial in detail before the trial, be able to understand the procedures and methods of this study, be willing to strictly abide by the clinical trial protocol to complete the trial, and voluntarily sign the informed consent form; 2. Elective thoracic surgery; 3. Age>=18 years old; 4. American Society of Anesthesiologists (ASA) grade I.~III.; 5. Patients using bupivacaine liposomal injection.

Exclusion criteria

Exclusion criteria: 1. Patients with psychiatric diseases and cognitive dysfunction; 2. Patients with sensory impairments such as hyperalgesia, or other physical pain that affects postoperative pain assessment; 3. History of myocardial infarction or unstable angina pectoris within half a year, or history of severe arrhythmia (if there is atrioventricular block of grade II or above); 4. Patients with diabetic peripheral neuropathy; 5. Known allergy to bupivacaine or other amide local anesthetics; 6. Pregnant and lactating patients, as well as female patients who have a birth plan within half a year and are unwilling or unable to take effective contraceptive measures; 7. Patients with any other factors that, in the opinion of the investigator, are not suitable for participation in this trial.

Design outcomes

Primary

MeasureTime frame
Incidence of severe pain;

Countries

China

Contacts

Public ContactXin Lv

Shanghai Pulmonary Hospital

xinlvg@126.com+86 136 6186 9972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026